Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
13.800
Open
13.470
VWAP
13.29
Vol
806.68K
Mkt Cap
625.99M
Low
13.030
Amount
10.72M
EV/EBITDA(TTM)
7.07
Total Shares
46.51M
EV
636.69M
EV/OCF(TTM)
8.52
P/S(TTM)
0.89
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
Show More

Events Timeline

(ET)
2026-02-24
07:10:00
Company Reports Q4 Revenue of $180.9M
select
2026-02-24
07:10:00
Sees 2026 Revenue at $700M-$720M
select
2026-01-20 (ET)
2026-01-20
08:10:00
Avanos Medical and Siemens Healthineers Announce Strategic Co-Marketing Agreement
select
2025-11-05 (ET)
2025-11-05
11:38:10
Avanos increases FY25 adjusted EPS forecast to 85c-95c, up from 75c-95c
select
2025-11-05
11:37:51
Avanos announces Q3 adjusted earnings per share of 22 cents, surpassing consensus estimate of 12 cents.
select
2025-10-23 (ET)
2025-10-23
08:03:23
Avanos to divest its US Game Ready orthopedic rental division to WRS Group
select
2025-09-15 (ET)
2025-09-15
07:06:14
Avanos Purchases Nexus Medical, Financial Details Not Revealed
select

News

PRnewswire
7.0
03-17PRnewswire
Purcell & Lefkowitz Investigates Avanos Medical for Shareholder Rights
  • Investigation Background: Purcell & Lefkowitz LLP is investigating Avanos Medical to determine whether the company's directors breached their fiduciary duties in recent corporate actions, which could impact shareholder rights.
  • Shareholder Rights Protection: The investigation focuses on safeguarding the interests of Avanos Medical shareholders, with the law firm offering free consultations to help shareholders understand their rights and options, demonstrating a commitment to shareholder welfare.
  • Legal Service Commitment: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud, breaches of fiduciary duty, and other corporate misconduct, highlighting its expertise in legal services.
  • Contact Information: Shareholders seeking more information can directly contact the law firm via email or phone, ensuring they receive professional legal advice at no cost or obligation.
PRnewswire
1.0
03-02PRnewswire
Avanos Medical to Speak at Citizens Life Sciences Conference
  • Executive Participation: Avanos Medical's CEO Dave Pacitti and CFO Scott Galovan will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11 at approximately 1:05 p.m. ET, showcasing the company's leadership in the medical technology sector.
  • Webcast Availability: The conference presentation will be available via a webcast on the Investors section of Avanos Medical's website and archived for later access, ensuring that investors and the public can stay informed and enhancing the company's transparency.
  • Company Mission: Avanos Medical focuses on delivering clinically superior medical device solutions aimed at addressing critical healthcare needs, including providing essential nutrition support to patients and reducing opioid use, thereby facilitating faster recovery for patients.
  • Global Market Position: Headquartered in Alpharetta, Georgia, Avanos Medical holds leading market positions across multiple product categories, demonstrating its strong competitive edge in the global medical device market.
Newsfilter
1.0
03-02Newsfilter
Avanos Medical to Speak at Citizens Life Sciences Conference
  • Executive Participation: Avanos Medical's CEO Dave Pacitti and CFO Scott Galovan will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11 at approximately 1:05 p.m. Eastern Time, showcasing the company's leadership in the medical technology sector.
  • Webcast Availability: The conference presentation will be available via a webcast on the Investors section of Avanos Medical's website and will be archived for later access, ensuring that investors and the public can easily access relevant information and enhancing transparency.
  • Mission Statement: Avanos Medical focuses on delivering clinically superior medical device solutions aimed at addressing significant healthcare needs, including providing vital nutrition support for patients and reducing opioid usage to facilitate recovery post-surgery.
  • Global Market Position: Headquartered in Alpharetta, Georgia, Avanos Medical holds leading market positions across multiple product categories, continuously developing, manufacturing, and marketing its recognized brands to improve patient quality of life.
PRnewswire
5.0
02-26PRnewswire
Avanos Medical Nominates New Directors for Board Election
  • Board Nominations: Avanos Medical has announced the nomination of Jim Cunniff, CEO of Electromed, Inc., and Bill Burke, former CFO of Haemonetics, as independent directors for election at the 2026 Annual Meeting, aiming to enhance the board's leadership and financial expertise.
  • Strategic Cooperation Agreement: This nomination is coupled with a cooperation agreement with Bradley L. Radoff and his affiliates, indicating Avanos's commitment to achieving long-term strategic goals through the introduction of new directors to improve governance.
  • Rich Industry Experience: Cunniff brings over 30 years of leadership experience in medical technology, having successfully driven revenue and profit growth in multiple companies, while Burke's extensive finance background in global medical technology is expected to have an immediate positive impact on Avanos.
  • Future Outlook: The Avanos board will formally recommend these nominees at the 2026 Annual Meeting, which is anticipated to further drive sustainable growth and enhance market competitiveness through the introduction of new perspectives and expertise.
seekingalpha
9.5
02-24seekingalpha
Avanos Medical Reports Strong Q4 2025 Earnings and Strategic Outlook
  • Strong Annual Performance: Avanos Medical reported full-year net sales of $701 million and adjusted EPS of $0.94 for 2025, despite tariff impacts; management is optimistic about future performance, projecting 2026 sales between $700 million and $720 million.
  • Portfolio Growth: The Specialty Nutrition Systems (SNS) segment achieved over 8% organic growth, with double-digit growth in short-term enteral feeding products driven by the expansion of CORTRAK and CORGRIP 2 systems, highlighting the company's competitive position in the market.
  • Cost Control Measures: Management anticipates $30 million in tariff costs for 2026, primarily affecting products sourced from China; however, plans are in place to mitigate long-term tariff risks, including exiting syringe manufacturing in China by June 2026.
  • Successful Acquisition Integration: Avanos's acquisition of Nexus Medical is progressing well, with management expressing confidence in future growth opportunities, expecting to enhance shareholder value through portfolio optimization and cost control.
PRnewswire
9.5
02-24PRnewswire
Avanos Medical Reports 2025 Financial Highlights
  • Financial Overview: Avanos Medical reported fourth-quarter net sales of $180.9 million, a slight increase of 0.7% year-over-year, while full-year net sales reached $701.2 million, up 1.9% from $687.8 million in 2024, indicating stability in the market.
  • Decline in Free Cash Flow: The company generated free cash flow of $21.3 million in Q4 2025, significantly down from $53.1 million a year earlier, with total free cash flow for 2025 at $43.1 million, compared to $82.9 million in the previous year, reflecting challenges in cost management and capital expenditures.
  • Goodwill Impairment Impact: Avanos recorded a $77 million goodwill impairment charge in Q2 2025 due to market capitalization pressures, negatively affecting the overall financial health of the company and resulting in a net loss of $72.9 million for the year.
  • Future Outlook: The company expects net sales for 2026 to be between $700 million and $720 million, with adjusted earnings per share projected between $0.90 and $1.10, indicating management's optimism for future growth despite ongoing market challenges.

Valuation Metrics

The current forward P/E ratio for Avanos Medical Inc (AVNS.N) is 11.65, compared to its 5-year average forward P/E of 17.13. For a more detailed relative valuation and DCF analysis to assess Avanos Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
17.13
Current PE
11.65
Overvalued PE
22.87
Undervalued PE
11.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.99
Undervalued EV/EBITDA
3.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.48
Current PS
0.74
Overvalued PS
1.99
Undervalued PS
0.98

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Stocks Bullish Tomorrow
Intellectia · 75 candidates
Moving Average Relationship: PriceAboveMA20Option Sentiments: BullishOne Day Rise Prob: >= 60One Day Predict Return: >= 1.0%Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
EHAB logo
EHAB
Enhabit Inc
554.91M
FET logo
FET
Forum Energy Technologies Inc
526.00M
BLFY logo
BLFY
Blue Foundry Bancorp
293.98M
GSBC logo
GSBC
Great Southern Bancorp Inc
704.33M
GORO logo
GORO
Gold Resource Corp
242.79M
AVNS logo
AVNS
Avanos Medical Inc
641.97M

Whales Holding AVNS

B
Blackhill Capital, Inc
Holding
AVNS
-6.60%
3M Return
A
Armistice Capital LLC
Holding
AVNS
-10.53%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Avanos Medical Inc (AVNS) stock price today?

The current price of AVNS is 13.05 USD — it has decreased -3.05

What is Avanos Medical Inc (AVNS)'s business?

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

What is the price predicton of AVNS Stock?

Wall Street analysts forecast AVNS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVNS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Avanos Medical Inc (AVNS)'s revenue for the last quarter?

Avanos Medical Inc revenue for the last quarter amounts to 180.90M USD, increased 0.72

What is Avanos Medical Inc (AVNS)'s earnings per share (EPS) for the last quarter?

Avanos Medical Inc. EPS for the last quarter amounts to -0.03 USD, decreased -99.65

How many employees does Avanos Medical Inc (AVNS). have?

Avanos Medical Inc (AVNS) has 2287 emplpoyees as of March 21 2026.

What is Avanos Medical Inc (AVNS) market cap?

Today AVNS has the market capitalization of 625.99M USD.